<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 11 (filtered medium)">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<style>
<!--
/* Font Definitions */
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman";}
a:link, span.MsoHyperlink
{color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{color:purple;
text-decoration:underline;}
span.emailstyle17
{font-family:Arial;
color:navy;}
span.EmailStyle18
{mso-style-type:personal-reply;
font-family:"Times New Roman";
color:blue;
font-weight:normal;
font-style:normal;
text-decoration:none none;}
@page Section1
{size:8.5in 11.0in;
margin:1.0in 1.25in 1.0in 1.25in;}
div.Section1
{page:Section1;}
-->
</style>
</head>
<body lang=EN-US link=blue vlink=purple>
<div class=Section1>
<div>
<p class=MsoNormal><font size=2 color=blue face="Times New Roman"><span
style='font-size:10.0pt;color:blue'>FYI</span></font><o:p></o:p></p>
</div>
<div>
<div class=MsoNormal align=center style='text-align:center'><font size=3
face="Times New Roman"><span style='font-size:12.0pt'>
<hr size=3 width="100%" align=center tabindex=-1>
</span></font></div>
<p class=MsoNormal><b><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma;font-weight:bold'>From:</span></font></b><font size=2
face=Tahoma><span style='font-size:10.0pt;font-family:Tahoma'> Discussion of
Research Administrators' Issues [mailto:RAMTALK@LISTSERV.ARIZONA.EDU] <b><span
style='font-weight:bold'>On Behalf Of </span></b>Sherry Esham<br>
<b><span style='font-weight:bold'>Sent:</span></b> Tuesday, February 24, 2009
10:58 AM<br>
<b><span style='font-weight:bold'>To:</span></b> RAMTALK@LISTSERV.ARIZONA.EDU<br>
<b><span style='font-weight:bold'>Subject:</span></b> Special Edition--From the
Acting NIH Director: American Recovery and Reinvestment Act of 2009
(ARRA)--NIH's role</span></font><o:p></o:p></p>
</div>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'><o:p> </o:p></span></font></p>
<p class=MsoNormal><font size=2 face=Tahoma><span style='font-size:10.0pt;
font-family:Tahoma'>-----Original Message-----<br>
<b><span style='font-weight:bold'>From:</span></b> COGR [mailto:cogr@usc.edu] <br>
<b><span style='font-weight:bold'>Sent:</span></b> Friday, February 20, 2009
9:00 PM<br>
<b><span style='font-weight:bold'>To:</span></b> cogr-list@usc.edu<br>
<b><span style='font-weight:bold'>Subject:</span></b> FW: Special Edition--From
the Acting NIH Director: American Recovery and Reinvestment Act of 2009
(ARRA)--NIH's role</span></font><o:p></o:p></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'> <o:p></o:p></span></font></p>
<p class=MsoNormal><font size=3 face="Times New Roman"><span style='font-size:
12.0pt'>sender: Tony DeCrappeo <TDeCrappo@cogr.edu> <br>
<br>
</span></font><font size=2><span style='font-size:10.0pt'>The following was
sent out from Raynard Kington, Acting Director of NIH:<br>
<br>
From the Acting NIH Director-<br>
<br>
On Tuesday, February 17, 2009, President Barack Obama signed the<br>
American Recovery & Reinvestment Act of 2009 (ARRA), the economic<br>
stimulus, into law. This is an extraordinarily challenging time for our<br>
entire country, and NIH is extremely grateful to President Obama and<br>
Congress for recognizing both the economic and health impacts of<br>
biomedical and behavioral research. The $10.4 billion of investment will<br>
have an impact beyond the funding horizon of this Act, as it also<br>
supports the economic stimulus.<br>
<br>
We are well positioned to fund the best science in pursuit of improving<br>
the length and the quality of the lives of our citizens, while at the<br>
same time stimulating the economy of the 50 states and territories,<br>
through more than 3,000 institutions we currently fund to conduct<br>
outstanding biomedical and behavioral research-- institutions that have<br>
a direct impact upon the local economies in their towns, cities, and<br>
states.<br>
<br>
The purpose of the ARRA is to:<br>
<br>
(1) preserve and create jobs and promote economic recovery.<br>
<br>
(2) assist those most impacted by the recession.<br>
<br>
(3) provide investments to increase economic efficiency by spurring<br>
technological advances in science and health.<br>
<br>
(4) invest in transportation, environmental protection, and other<br>
infrastructure that will provide long-term economic benefits.<br>
<br>
(5) stabilize state and local government budgets, in order to minimize<br>
and avoid reductions in essential services and counterproductive state<br>
and local tax increases.<br>
<br>
As we learned about NIH's possible inclusion in the national economic<br>
recovery effort, we worked around the clock to prepare to make the most<br>
effective use of these extraordinary resources. NIH grants support jobs<br>
and the economy of local communities, and we are preparing to move the<br>
funds quickly as we manage and track the impact on economic recovery, as<br>
well as the progress on improving human health in a way that increases<br>
transparency for the public. We are waiting for guidance from the<br>
Department of Health and Human Services and the White House, and no<br>
funding decisions have been made. <br>
<br>
<br>
NIH Funding<br>
<br>
The stimulus bill provides a total of $10.4 billion, all available for<br>
two years--through September 2010. We expect to spend as much as<br>
possible in FY 2009 to support the goals of the ARRA and advance<br>
scientific priorities. (Note that none of these resources are added to<br>
the NIH's future base funding level). Below is a summary:<br>
<br>
-$8.2 billion in support of scientific research priorities<br>
<br>
o $7.4 billion is transferred to the
Institutes and Centers and<br>
Common Fund (CF), based on a percentage-based formula<br>
<br>
o $800 million to the Office of the
Director (OD) (not including<br>
CF)<br>
<br>
(For example, support for Challenge<br>
Grants), a program designed to focus on health and science problems<br>
where progress can be expected in two years.<br>
<br>
o To support additional scientific
research-related activities<br>
that also align with the overall purposes of the Act<br>
<br>
-$1 billion to support Extramural Construction, Repairs, and Alterations<br>
<br>
o Allocated to the National Center for
Research Resources (NCRR)<br>
in support of all NIH funded research institutions<br>
<br>
-$300 million for Shared Instrumentation and other capital equipment<br>
<br>
o Allocated to NCRR to support all NIH
activities<br>
<br>
-$500 million for NIH buildings and facilities<br>
<br>
o To fund high priority repair,
construction and improvement<br>
projects on NIH campuses that also align with the overall purpose of the<br>
Act<br>
<br>
-$400 million for Comparative Effectiveness Research (CER)<br>
<br>
Many types of funding mechanisms will be supported, but, in general, NIH<br>
will focus scientific activities in several areas:<br>
<br>
1) We will choose among recently peer reviewed, highly meritorious R01<br>
and similar mechanisms capable of making significant advances in two<br>
years. R01 are projects proposed directly from scientists across the<br>
country.<br>
<br>
2) We will also fund new R01 applications that have a reasonable<br>
expectation of making progress in two years. The adherence to this time<br>
frame is in direct response to the spirit of the law.<br>
<br>
3) We will accelerate the tempo of ongoing science through targeted<br>
supplements to current grants. For example, we may competitively expand<br>
the scope of current research awards or supplement an existing award<br>
with additional support for infrastructure (e.g., equipment) that will<br>
be used in the two-year availability of these funds.<br>
<br>
4) NIH anticipates supporting new types of activities that fit into the<br>
structure of the ARRA. For example, it will support a reasonable number<br>
of awards to jump start the new NIH Challenge Grant program. This<br>
program is designed to focus on health and science problems where<br>
progress can be expected in two years. The number of awards and amount<br>
of funds will be determined, based on the scientific merit and the<br>
quality of applications. I anticipate-out of the OD funds in the<br>
ARRA--NIH will support at least $100 to $200 million-but the science<br>
will drive the actual level.<br>
<br>
5) We will also use other funding mechanisms as appropriate.<br>
<br>
The impact of this stimulus to scientists cannot be overstated. The<br>
impact extends far beyond the current economic challenges and immediate<br>
scientists who will receive funds, to allied health workers,<br>
technicians, students, trade workers and others who will receive the<br>
leveraged benefits.<br>
<br>
We understand to accomplish the goals of ARRA, it will take the help of<br>
the entire scientific community. Beyond the immediate economic stimulus,<br>
the long-term impact from the science funded by the ARRA will have a<br>
positive impact upon the health of the nation for years to come.<br>
<br>
The ARRA is complex, with multi-layered reporting requirements. NIH is<br>
working with the Administration to ensure transparency and<br>
accountability. In the near future, NIH will post information about its<br>
role in the recovery and impact on RECOVERY.gov<br>
<br>
We are committed, with the outstanding support that has been given by<br>
the White House, the Department, and Congress, to make our decisions<br>
based on best scientific opportunity and public need. We will seek<br>
projects with the broadest impact, work that can be accomplished in two<br>
years, that relies heavily on our new streamlined, modernized peer<br>
review system. This is not a time for business as usual nor formulaic<br>
solutions; this is a time for true innovation, energy, and recovery.<br>
<br>
Again, NIH is grateful to all of you who will work with us to<br>
successfully implement this important contribution to our national<br>
health and economic recovery.<br>
<br>
Please, contact me with any comments. NIHKingtonDirect@mail.nih.gov<br>
<br>
Raynard S. Kington, M.D., Ph.D., Acting Director, National Institutes of<br>
Health</span></font><o:p></o:p></p>
</div>
</body>
</html>